These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Understanding the basis of resistance in the irksome Lys103Asn HIV-1 reverse transcriptase mutant through targeted molecular dynamics simulations. Rodríguez-Barrios F; Gago F J Am Chem Soc; 2004 Dec; 126(47):15386-7. PubMed ID: 15563158 [TBL] [Abstract][Full Text] [Related]
9. Synthesis, biological evaluation and molecular modeling studies of N-aryl-2-arylthioacetamides as non-nucleoside HIV-1 reverse transcriptase inhibitors. Xiaohe Z; Yu Q; Hong Y; Xiuqing S; Rugang Z Chem Biol Drug Des; 2010 Oct; 76(4):330-9. PubMed ID: 20731670 [TBL] [Abstract][Full Text] [Related]
10. New pyridinone derivatives as potent HIV-1 nonnucleoside reverse transcriptase inhibitors. Le Van K; Cauvin C; de Walque S; Georges B; Boland S; Martinelli V; Demonté D; Durant F; Hevesi L; Van Lint C J Med Chem; 2009 Jun; 52(12):3636-43. PubMed ID: 19469474 [TBL] [Abstract][Full Text] [Related]
11. Design, synthesis and antimicrobial activities of nitroimidazole derivatives containing 1,3,4-oxadiazole scaffold as FabH inhibitors. Li Y; Luo Y; Hu Y; Zhu DD; Zhang S; Liu ZJ; Gong HB; Zhu HL Bioorg Med Chem; 2012 Jul; 20(14):4316-22. PubMed ID: 22710102 [TBL] [Abstract][Full Text] [Related]
12. Conformationally constrained analogs of N-substituted piperazinylquinolones: synthesis and antibacterial activity of N-(2,3-dihydro-4-hydroxyimino-4H-1-benzopyran-3-yl)-piperazinylquinolones. Emami S; Foroumadi A; Samadi N; Faramarzi MA; Rajabalian S Arch Pharm (Weinheim); 2009 Jul; 342(7):405-11. PubMed ID: 19544301 [TBL] [Abstract][Full Text] [Related]
13. A pharmacophore docking algorithm and its application to the cross-docking of 18 HIV-NNRTI's in their binding pockets. Daeyaert F; de Jonge M; Heeres J; Koymans L; Lewi P; Vinkers MH; Janssen PA Proteins; 2004 Feb; 54(3):526-33. PubMed ID: 14748000 [TBL] [Abstract][Full Text] [Related]
14. Fused heterocycles bearing bridgehead nitrogen as potent HIV-1 NNRTIs. Part 4: design, synthesis and biological evaluation of novel imidazo[1,2-a]pyrazines. Huang B; Liang X; Li C; Chen W; Liu T; Li X; Sun Y; Fu L; Liu H; De Clercq E; Pannecouque C; Zhan P; Liu X Eur J Med Chem; 2015 Mar; 93():330-7. PubMed ID: 25707013 [TBL] [Abstract][Full Text] [Related]
16. Design, synthesis, and SAR of a novel pyrazinone series with non-nucleoside HIV-1 reverse transcriptase inhibitory activity. Heeres J; de Jonge MR; Koymans LM; Daeyaert FF; Vinkers M; Van Aken KJ; Arnold E; Das K; Kilonda A; Hoornaert GJ; Compernolle F; Cegla M; Azzam RA; Andries K; de Béthune MP; Azijn H; Pauwels R; Lewi PJ; Janssen PA J Med Chem; 2005 Mar; 48(6):1910-8. PubMed ID: 15771435 [TBL] [Abstract][Full Text] [Related]
17. Outsmarting HIV drug resistance. Balter M Science; 1998 Nov; 282(5394):1623, 1625. PubMed ID: 9867659 [No Abstract] [Full Text] [Related]
18. Revealing interaction mode between HIV-1 reverse transcriptase and diaryltriazine analog inhibitor. Li Z; Han J; Chen HF Chem Biol Drug Des; 2008 Nov; 72(5):350-9. PubMed ID: 19012571 [TBL] [Abstract][Full Text] [Related]
19. Synthesis and studies of new 2-(coumarin-4-yloxy)-4,6-(substituted)-S-triazine derivatives as potential anti-HIV agents. Mahajan DH; Pannecouque C; De Clercq E; Chikhalia KH Arch Pharm (Weinheim); 2009 May; 342(5):281-90. PubMed ID: 19415671 [TBL] [Abstract][Full Text] [Related]
20. Discovery of a 1,5-dihydrobenzo[b][1,4]diazepine-2,4-dione series of inhibitors of HIV-1 capsid assembly. Fader LD; Bethell R; Bonneau P; Bös M; Bousquet Y; Cordingley MG; Coulombe R; Deroy P; Faucher AM; Gagnon A; Goudreau N; Grand-Maître C; Guse I; Hucke O; Kawai SH; Lacoste JE; Landry S; Lemke CT; Malenfant E; Mason S; Morin S; O'Meara J; Simoneau B; Titolo S; Yoakim C Bioorg Med Chem Lett; 2011 Jan; 21(1):398-404. PubMed ID: 21087861 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]